1-3 of 3
Shinichi Hasako
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations

Free
Shinichi Hasako, Miki Terasaka, Naomi Abe, Takao Uno, Hirokazu Ohsawa, Akihiro Hashimoto, Ryoto Fujita, Kenji Tanaka, Takashige Okayama, Renu Wadhwa, Kazutaka Miyadera, Yoshimi Aoyagi, Kazuhiko Yonekura, Kenichi Matsuo
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (8): 1648–1658.
https://doi.org/10.1158/1535-7163.MCT-17-1206
Published: 31 July 2018
View articletitled, TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Open the PDF for TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations in another window
Includes: Supplementary data
Journal Articles

Abstract A158: Characterization of antitumor activity of TAS6417, a novel EGFR-TKI targeting exon 20 insertions

Free
Shinichi Hasako, Miki Terasaka, Ryoto Fujita, Naomi Abe, Akihiro Hashimoto, Kenichi Matsuo, Teruhiro Utsugi, Yoshikazau Iwasawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A158.
https://doi.org/10.1158/1535-7163.TARG-17-A158
Published: 01 January 2018
View articletitled, Abstract A158: Characterization of antitumor activity of TAS6417, a novel EGFR-TKI targeting exon 20 insertions
Journal Articles

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

Free
Toshiyasu Shimomura, Shinichi Hasako, Yoko Nakatsuru, Takashi Mita, Koji Ichikawa, Tsutomu Kodera, Takumi Sakai, Tadahiro Nambu, Mayu Miyamoto, Ikuko Takahashi, Satomi Miki, Nobuhiko Kawanishi, Mitsuru Ohkubo, Hidehito Kotani, Yoshikazu Iwasawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 157–166.
https://doi.org/10.1158/1535-7163.MCT-09-0609
Published: 12 January 2010
View articletitled, MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
Open the PDF for MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel in another window
Includes: Supplementary data